“As we mark World AIDS Day on December 1st, despite all the recent setbacks due to the ongoing COVID-19 epidemic, there is hope on the horizon for ending HIV in the United States,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “President Biden is set to release an updated National HIV/AIDS Strategic Plan and several bills have been or are about to be introduced in Congress to establish a national PrEP program to prevent HIV. Additionally, Congress is poised to increase funding for domestic HIV programs for the year ahead. Taken together, these are hopeful signs. However, for these well-intentioned plans to be implemented, much work still needs to occur.”
Biden Budget Proposes Increased Funding for Ending HIV
Washington DC… In President Biden’s first preliminary budget that was released today, he is proposing to continue to ramp up efforts to end HIV in the United States with an increase of $267 million for domestic HIV testing, prevention, and treatment programs as part of the Ending the HIV Epidemic Initiative.
Biden administration passes on protecting patient affordability of medications
“We are deeply disappointed that CMS passed on addressing the issue of copay assistance for prescription drugs and requiring insurers and pharmacy benefit managers (PBMs) to count assistance towards patient out-of-pocket cost-sharing and deductibles,” commented Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.
Biden budget proposes increased funding for ending HIV
Washington DC… In President Biden’s first preliminary budget that was released today, he is proposing to continue to ramp up efforts to end HIV in the United States with an increase of $267 million for domestic HIV testing, prevention, and treatment programs as part of the Ending the HIV Epidemic Initiative.
Biden administration pulls last-minute Trump Medicare drug demo plan
Washington DC… In a victory for patients who depend on Medicare Part D for their medications, the Biden administration has pulled a demonstration project that would have allowed participating Medicare plans in 2022 to not cover all drugs in certain classes and only one drug per class in all others. The proposal that was pulled was announced literally in the final hours of the Trump administration.